Acute Radiation Syndrome - Pipeline Insight, 2024

This “Acute Radiation Syndrome - Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Acute Radiation Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Acute Radiation Syndrome: Understanding

Acute Radiation Syndrome: Overview

Acute Radiation Syndrome is a broad term used to describe a range of signs and symptoms that reflect severe damage to specific organ systems and that can lead to death within hours or up to several months after exposure.

Acute radiation syndrome can result from direct exposure to high levels of radiation, such as from a nuclear blast, or contamination by radioactive materials through ingestion, skin contact, or inhalation. It is categorized into three groups: hematopoietic, gastrointestinal, and neurovascular syndromes, each requiring different radiation doses to exhibit symptoms. The onset of symptoms follows a distinct pattern with a prodromal phase occurring 0-2 days post-exposure, a latent phase from 2-20 days, and a manifest illness phase from 21-60 days after exposure.

The key signs and symptoms of Acute Radiation Syndrome (ARS) include:

1. Hematopoietic syndrome:

• Drop in blood cell counts, leading to infections, bleeding, and anemia
• Can occur at doses as low as 0.25 Gy (25 rad)

2. Gastrointestinal syndrome:

• Nausea, vomiting, loss of appetite, abdominal pain
• Often follows doses of 6-30 Gy (600-3,000 rad)

3. Neurovascular syndrome:

• Neurological symptoms like dizziness, headache, decreased consciousness
• Typically occurs at doses greater than 30 Gy (3,000 rad), though can occur at 10 Gy (1,000 rad)
• Almost always fatal even with aggressive treatment

Other common early symptoms include nausea, vomiting, headaches, fatigue, fever, and skin reddening, which can occur at doses as low as 0.35 Gy (35 rad).

After a radiation emergency, the priority is to protect staff and patients from contamination. Removing any contaminated clothing can decrease exposure by 80%. Patients with life-threatening injuries should be decontaminated as much as possible, but surgical and trauma emergencies take priority. Supportive care is crucial for acute radiation syndrome, including fluid management, infection treatment, and prevention of thyroid cancer. All children and pregnant women should be given potassium iodide to protect the thyroid, and breastfeeding mothers should stop if possible. Anti-emetics, pain control, and early use of antibiotics are also important. Bone marrow transplants and chelating agents may be used in severe cases, but only after consultation with a nuclear specialist. The psychological trauma, especially in children, must also be addressed.

"Acute Radiation Syndrome - Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Radiation Syndrome pipeline landscape is provided which includes the disease overview and Acute Radiation Syndrome treatment guidelines. The assessment part of the report embraces, in depth Acute Radiation Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Radiation Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute Radiation Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Acute Radiation Syndrome.

Acute Radiation Syndrome Emerging Drugs Chapters

This segment of the Acute Radiation Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute Radiation Syndrome Emerging Drugs

STAT-600: Statera BioPharma

STAT-600 is a Toll-like receptor 5 (TLR5) agonist, which is developed as a radiation countermeasure for prevention of death from acute radiation syndrome, and as an oncology drug. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients suffering from acute radiation syndrome.

NT-17: NeoImmuneTech

NT-I7 (efineptakin alfa) (rhIL-7-hyFc) is the only clinical-stage long-acting human IL-7 and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. The drug is currently being evaluated in preclinical stage of development for the treatment of acute radiation syndrome.

Acute Radiation Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Acute Radiation Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute Radiation Syndrome

There are approx. 5+ key companies which are developing the therapies for Acute Radiation Syndrome. The companies which have their Acute Radiation Syndrome drug candidates in the most advanced stage, i.e. Phase I include, Statera BioPharma.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Acute Radiation Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Radiation Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Radiation Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Radiation Syndrome drugs.

Acute Radiation Syndrome Report Insights

• Acute Radiation Syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acute Radiation Syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acute Radiation Syndrome drugs?
• How many Acute Radiation Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Radiation Syndrome?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute Radiation Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute Radiation Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Statera BioPharma
• NeoImmuneTech
• Chrysalis BioTherapeutics

Key Products

• STAT-600
• NT-17
• TP508

This product will be delivered within 2 business days.